RNAi modulation of ApoB and uses thereof
View Patent ↗The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
1. A method of reducing the amount of ApoB RNA in a cell, comprising: contacting the cell with an iRNA agent, wherein said iRNA comprises a sense strand having at least 17 contiguous nucleotides of the sense strand sequence of iRNA agent 35 (SEQ ID NO:5), and an antisense strand having at least 15 contiguous nucleotides of the antisense sequence of iRNA agent number 35 (SEQ ID NO:6).
2. The method of claim 1 , wherein the cell is contacted with the iRNA agent in vitro.
3. The method of claim 1 , wherein the cell is contacted with the iRNA agent in a subject in-vivo.
4. The method of claim 3 , wherein the subject is diagnosed as having a hypercholesterolemia, a hyperlipidemia, coronary artery disease (CAD), coronary heart disease, thrombosis, or atherosclerosis.
5. The method of claim 4 , wherein the subject is diagnosed as having a lipid disorder.
6. The method of claim 5 , wherein the subject is diagnosed as having a hypercholesterolemia, a hyperlipidemia, coronary artery disease, coronary heart disease, thrombosis, or atherosclerosis.
7. The method of claim 6 wherein the subject is a human.
8. A method of treating a human subject having or at risk for developing a lipid disorder comprising administering an iRNA agent, wherein the iRNA agent comprises a sense strand having at least 17 contiguous nucleotides of the sense strand sequence of iRNA agent 35 (SEQ ID NO:5), and an antisense strand having at least 15 contiguous nucleotides of the antisense sequence of iRNA agent number 35 (SEQ ID NO:6).
9. The method of claim 8 , wherein the lipid disorder is a hypercholesterolemia, a hyperlipidemia, coronary artery disease, coronary heart disease, thrombosis, or atherosclerosis.
10. The method of claim 8 , wherein the iRNA agent is administered in an amount sufficient to reduce the expression of ApoB in a cell or tissue of the subject.